Last Updated : May 1, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| XGEVA | Denosumab | Prevention of skeletal-related events due to bone metastases from solid tumours | List with clinical criteria and/or conditions | Complete | ||
| Xgeva | Denosumab (Drug Plan Submission) | Prevention of skeletal-related events due to bone metastases from other solid tumors (excluding breast and prostate cancer), including non-small cell lung cancer | List with clinical criteria and/or conditions | Complete | ||
| Xiaflex | Collagenase clostridium histolyticum | Dupuytren’s contracture | List with criteria/condition | Complete | ||
| XigDuo | dapagliflozin/metformin hydrochloride | Diabetes Mellitus, Type 2 | Reimburse with clinical criteria and/or conditions | Complete | ||
| Xofluza | baloxavir marboxil | Influenza | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | |||
| Xolair | omalizumab | Chronic rhinosinusitis with nasal polyps | CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer | Not filed | ||
| Xolair | Omalizumab | Chronic idiopathic urticaria | List with clinical criteria and/or conditions | Complete | ||
| Xolair | Omalizumab | Asthma, severe persistent | Cancelled | |||
| Xolair | Omalizumab | Asthma, severe persistent | Do not list | Complete | ||
| Xolair | Omalizumab (Drug Plan Submission) | Asthma, severe persistent | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : May 1, 2024